Leveraging a novel platform technology to develop a first-in-class immunotherapy for celiac disease
Celiac Disease is a debilitating autoimmune disorder that is caused by intolerance to gluten. Although it is the most common genetically-based food intolerance in the world, there are currently no therapeutics available to treat patients. In this project, Allero Therapeutics will collaborate with two leading research institutes (Leiden University Medical Center from the Netherlands and the Veterinary Research Institute from the Czech Republic) to develop a first-in-class therapeutic against Celiac Disease. Specifically, this novel therapeutic consists of an antigen-specific immunotherapy combined with tolerizing agents, which will be delivered to the oromucosa via a proprietary sublingual mouth patch. This project consists of a 6-month multi-disciplinary feasibility study that will:

(1) experimentally demonstrate in vitro and ex vivo Proof of Principle for the novel therapeutic; 
(2) research all required (pre)clinical development to build a detailed roadmap for navigating the regulatory landscape; 
(3) strengthen and expand the current IP position; and 
(4) consolidate all current and future findings into an investor-ready Business Plan.